PD-L1和sPD-L1作为肝癌免疫治疗标志物的研究进展

Research progress of PD-L1 and sPD-L1 as biomarkers of hepatocellular carcinoma immunotherapy

肝细胞癌(HCC)是最常见的肝脏原发性肿瘤。研究显示免疫治疗可使更多的HCC患者受益,PD-1/PD-L1检查点抑制剂是癌症免疫治疗中最有前景的治疗策略。然而仍只有少数HCC患者从中受益,因此选择生物标记物来指导个性化抗PD-1的治疗使更多的患者受益尤为重要。PD-L1是PD-1的主要配体,sPD-L1是由PD-L1蛋白膜裂解释放,同样可与PD-1受体结合。PD-L1与sPD-L1已被证实在多种肿瘤中可作为预后标志物。而这两者在HCC患者中的表达及其预后价值仍有争议,本文将阐述PD-L1与sPD-L1在HCC患者中研究进展。

Hepatocellular carcinoma(HCC)is the most common primary tumor of the liver.Studies show that immunotherapy can benefit more HCC patients.PD-1/PD-L1 checkpoint inhibitor is the most promising treatment strategy in cancer immunotherapy.However,only a minority of HCC patients benefit from this therapy,so it is particularly important to select biomarkers to guide personalized anti-PD-1 treatment to benefit more patients.PD-L1 is the main ligand of PD-1.sPD-L1 is released by the cleavage of PD-L1 protein membrane,which also can bind to PD-1 receptors.PD-L1 and sPD-L1 have been proved to be prognostic markers in many tumors.The expression and prognostic value of PD-L1 and sPD-L1 in HCC patients are still controversial.This article will review the research progress of PD-L1 and sPD-L1 in HCC.